BGICC25 Updates: Dr. Matti Aapro on CDK4/6 Inhibitors in Breast Cancer
The 17th BGICC (Breast Gynecological and Immunooncology International Cancer Conference) was held on 23rd-24th January 2025 at the Hilton Heliopolis Hotel in Cairo, Egypt. This conference, recognized as the largest and most prestigious cancer event in Africa and the Middle East, served as a major platform for discussing the latest updates and trends in breast and gynecological cancers.
Under the slogan “Illumination and Creation,” it also highlighted advancements in genetics and immuno-oncology, covering all oncology aspects from diagnosis to future innovations. The event featured a range of scientific and educational symposia, workshops, debates, and recommendation sessions, with collaborations from world-renowned scientists and esteemed societies.
Dr. Matti Aapro, President, SPCC, Switzerland, joins OncoDaily at BGICC 2025 to discuss the use of CDK4/6 inhibitors in metastatic breast cancer. He shares insights from the SuFIA study, highlighting when hormone therapy alone may suffice before introducing CDK4/6 inhibitors. Tune in to explore personalized treatment strategies, cost considerations, and the potential role of these inhibitors in adjuvant settings.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023